A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy

ClinicalTrials.gov ID: NCT02864251

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02864251. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 5:30 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Open-Label, Randomized Trial of Nivolumab (BMS-936558) Plus Pemetrexed/Platinum or Nivolumab Plus Ipilimumab (BMS-734016) vs Pemetrexed Plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor Therapy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The main purpose of this study is to determine whether nivolumab + chemotherapy is effective as compared to chemotherapy in the treatment of patients with EGFR mutation, NSCLC who failed first line (1L) or second-line (2L) EGFR TKI therapy.

Study identification

NCT ID: NCT02864251
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Bristol-Myers Squibb; Industry
Enrollment: 367 participants

Conditions and interventions

Conditions

Non-Small-Cell Lung Carcinoma

Interventions

Nivolumab Biological
Ipilimumab Biological
Pemetrexed Drug
Cisplatin Drug
Carboplatin Drug

Biological · Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 17, 2017 (Actual)
Primary completion: Jan 20, 2022 (Actual)
Completion: Oct 17, 2022 (Actual)
Last update posted: Sep 28, 2023

2017 – 2022

United States locations

U.S. sites: 18
U.S. states: 10
U.S. cities: 15

Facility	City	State	ZIP	Site status
Pacific Shores Medical Group	Long Beach	California	90808	—
Local Institution - 0029	Los Angeles	California	90017	—
Local Institution - 0033	Los Angeles	California	90095	—
Local Institution - 0061	Orange	California	92868	—
Torrance Memorial Physican Network	Redondo Beach	California	90277	—
Local Institution - 0003	New Haven	Connecticut	06520	—
Local Institution - 0004	Chicago	Illinois	60637	—
Johns Hopkins University	Baltimore	Maryland	21205	—
Local Institution - 0002	Boston	Massachusetts	02114	—
Beth Israel Deaconess Medical Center	Boston	Massachusetts	02215	—
Dana Farber Cancer Institute	Boston	Massachusetts	02215	—
Local Institution - 0064	New York	New York	10016	—
Duke University Medical Center	Butner	North Carolina	27509-1626	—
Fox Chase Cancer Center	Philadelphia	Pennsylvania	19111	—
Texas Health Physicians Group	Arlington	Texas	76012	—
Baylor Scott and White Research Institute	Temple	Texas	76508	—
Local Institution - 0063	Tyler	Texas	75701	—
Local Institution - 0001	Salt Lake City	Utah	84112	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 91 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02864251, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 28, 2023 · Synced Nov 13, 2026